Clinical Trials Browser

INDUSTRY × Interventional × infigratinib × Clear all

NCT06206278 2024-08-14

Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer or GEJ Adenocarcinoma

Phase 2 Terminated

Gastrointestinal

Stomach Neoplasms

NCT03773302 2024-05-08

Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations

Phase 3 Terminated

48 enrolled 26 charts

Gastrointestinal

Cholangiocarcinoma

NCT04197986 2024-03-13

PROOF302

Phase 3 Terminated

39 enrolled 31 charts

Upper Tract Urothelial Carcinomas

NCT02159066 2024-03-05

LOGIC-2

Phase 2 Completed

158 enrolled 40 charts

Melanoma

NCT02150967 2023-07-03

A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma

Phase 2 Terminated

143 enrolled 25 charts 1 FDA

Gastrointestinal

Cholangiocarcinoma

NCT05222165 2023-02-23

NEWEL

Phase 1/2 Withdrawn

Central Nervous System Neoplasms

NCT05019794 2022-06-27

FGFR

Phase 2 Unknown

Gastrointestinal

Acrocephalosyndactylia, Stomach Neoplasms

NCT01928459 2020-12-09

Phase 1b Trial of BGJ398/BYL719 in Solid Tumors

Phase 1 Completed

Acrocephalosyndactylia, Breast Neoplasms

NCT01697605 2020-12-08

A Phase I Study of Oral BGJ398 in Asian Patients

Phase 1 Completed

Tumor With Alterations of the FGF-R

NCT01975701 2019-12-04

A Phase 2 Study of BGJ398 in Patients With Recurrent GBM

Phase 2 Completed

26 enrolled 10 charts

Glioblastoma

NCT01004224 2019-10-04

A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies

Phase 1 Completed

GenitourinaryThoracic

Urinary Bladder Neoplasms, Lung Neoplasms

NCT02160041 2019-06-18

CBGJ398XUS04

Phase 2 Terminated

84 enrolled 15 charts

Other hematologic neoplasm

Hematologic Neoplasms